Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...
Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...
On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.77 which represents a decrease of $-0.40 or -1.53% from the prior close of $26.17. The stock opened at $26.16 and touched a low ...
Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...
Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
The drug company had been searching for a new chief scientific officer since July with Mikael Dolsten leaving after 15 years ...
The world’s largest pharmaceutical company by 2023 revenue, Pfizer Inc. (PFE) is down more than 13% year-to-date, while the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback